Articles: adult.
-
Comment Randomized Controlled Trial
In adults hospitalized with COVID-19, adding remdesivir to standard care did not reduce in-hospital mortality.
Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ. 2022;194:E242-51. 35045989.
-
Randomized Controlled Trial
Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma.
Black and Latinx patients bear a disproportionate burden of asthma. Efforts to reduce the disproportionate morbidity have been mostly unsuccessful, and guideline recommendations have not been based on studies in these populations. ⋯ Among Black and Latinx adults with moderate-to-severe asthma, provision of an inhaled glucocorticoid and one-time instruction on its use, added to usual care, led to a lower rate of severe asthma exacerbations. (Funded by the Patient-Centered Outcomes Research Institute and others; PREPARE ClinicalTrials.gov number, NCT02995733.).
-
Randomized Controlled Trial
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.
Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan-human-coronavirus activity in vitro. ⋯ Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.).
-
Minerva anestesiologica · Apr 2022
Randomized Controlled TrialEffect of ultrasound angle for radial artery cannulation in adults: a randomized controlled trial.
Although the first attempt success rate of radial artery cannulation has been significantly improved by using dynamic needle tip positioning (DNTP) method, there are still problems with long cannulation time. We hereby observe the effect of ultrasound angle for radial artery cannulation in adult patients. ⋯ The usage of the U-P-needle approach could remarkably reduce radial arterial cannulation time at the first attempt as well as total puncture procedure duration, comparing with the U-P-artery approach.
-
Southern medical journal · Apr 2022
Randomized Controlled TrialCOVID-19 Trials: Who Participates and Who Benefits?
The coronavirus disease 2019 (COVID-19) pandemic has disproportionately afflicted vulnerable populations. Older adults, particularly residents of nursing facilities, represent a small percentage of the population but account for 40% of mortality from COVID-19 in the United States. Racial and ethnic minority individuals, particularly Black, Hispanic, and Indigenous Americans have experienced higher rates of infection and death than the White population. Although there has been an unprecedented explosion of clinical trials to examine potential therapies, participation by members of these vulnerable communities is crucial to obtaining data generalizable to those communities. ⋯ The high rate of nonparticipation in our trial of nursing facility residents and Black people emphasizes the concern that clinical trials for therapeutics may not target key populations with high mortality rates.